{"name":"Asana BioSciences","slug":"asana-biosciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ASN007 RD","genericName":"ASN007 RD","slug":"asn007-rd","indication":"Other","status":"phase_1"},{"name":"ASN007: ascending doses","genericName":"ASN007: ascending doses","slug":"asn007-ascending-doses","indication":"Other","status":"phase_1"},{"name":"ASN008 TG","genericName":"ASN008 TG","slug":"asn008-tg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ASN007 RD","genericName":"ASN007 RD","slug":"asn007-rd","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASN007: ascending doses","genericName":"ASN007: ascending doses","slug":"asn007-ascending-doses","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASN008 TG","genericName":"ASN008 TG","slug":"asn008-tg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNcTJnVHl4bUFFbF93Y2V4RlpsZDB1ektuNTI4VzB5aXlfUjU4NnF2Z3QwY3VISmw3dkhLT1dfTU5FdlkyWVc1bEU5UW80MzY4R1VtSTRKZXc4RnVrRUJqdHFma0EyTkpLbkRqY1ZiTDlFUHN6QmxDaXV5OG5mTGdhMmgwNTVEOVBQS0dDQ3NMbExHQmhvNWZlcGhadHBnUjAyR3pTS1VnbUIwbUhjYnRrRG5qMmtVMUFCRkJOZExzUW03VjNzRlY2NHhXa1R3dF9mVjJsdkg1REpCLVZVaTEwNlgzdTJRWkJyVzBjMGFkVVJwdE9ka1QtdllYNmFhT1dZc2Y3ckFXb3pHLUFtV1NZNFJiTExkVHBaMjQ3SUdNQ0pHelVleTN5NTMwQjRLU1UzX0ZRdGhqSjY5VEx0d1dncXJZYUdfQm5BbzdhZ1hyQQ?oc=5","date":"2026-03-23","type":"regulatory","source":"Barchart.com","summary":"Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research - ","headline":"Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"globenewswire.com","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - globenewswire.com","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1FUHIzWUVnRUNDaXR2Y2hSR0xMbWxQYm55TGZwUkdGREJWTFJpTkFudW1HWHNPRHI5SUZWdXFJeVJVWjJLVmJfcTZKVHRrQ19QV1I4eUgzTzNqTC1Qa3QxQVdaTXhIRGpCeVE?oc=5","date":"2025-08-28","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMm45RkRtdDVVc1dDTnpXT19yWndqZDFUR0dPWk53NkJtQzV0VVVKaGk3YmJsOTNDSWM5RjFxRmN3S1NoUWMydncyZzgxNUZIdTVEQkRhWHk1dmlRU3A2TkRsX3FZc2VDWjdwdjFRYTBNSEl2WWVwbkJ3dVlGbVp6ZjkzX0lvbC02U0VqUWpzR1pzYlB1R2c?oc=5","date":"2025-07-24","type":"regulatory","source":"Fierce Pharma","summary":"Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema - Fierce Pharma","headline":"Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNb3ZJMUMxSmdMQVYtN0k3YVVQZkZWaXBHemUzZUpJcUpKWjFiTHktbGdHZmRhMGlRZ2NvcFl2M0hOT1RXVlJYOVkwWFFUOFNMdTJCWTdXRnNmMHpTZ2p0Vnh1a3BWbzdPeno1OUZnb1J2YWIwdDVqX0oxOWw1RHk1VGVOb0JhTnBBdWRfdVZyNmpjaERzOFE?oc=5","date":"2025-06-24","type":"deal","source":"The Pharma Letter","summary":"Sanofi licenses gusacitinib from Formation Bio - The Pharma Letter","headline":"Sanofi licenses gusacitinib from Formation Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE15THdJbnVPcmN2b19FUWg4aWRWRFU1VlJDV0RYdW1wV1NCTjN5a0ZIOENSMnBMSUE3eEZUaEVEeUI5OEJzQmJTbFJpZ0g3SzFWNUlJ?oc=5","date":"2025-06-23","type":"deal","source":"FirstWord Pharma","summary":"Sanofi licenses Formation Bio's JAK/SYK inhibitor for up to €545M - FirstWord Pharma","headline":"Sanofi licenses Formation Bio's JAK/SYK inhibitor for up to €545M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxORUFLdm82aTlnRkJIb0FHQk5DZXNsbEhsWlNKYnRzVjNEQzY1MkNBdTh3WmZIRTl0M2YtcWVLcHI4Z1A4VElqZ1FWejBZa2N4YXBBWXk4TmxyRjRCZUlwREhlWTh5b2ZYOWwtODZKSHJuRHNoR1lxakNDd2ctblJublAtNDJiVzFMbkxWS1ZrVV9Ra09WUU9TV0tQWTVneUVEd0poUGJGXzVOWXFNMjlhbzNyQXJyZw?oc=5","date":"2025-06-23","type":"deal","source":"Fierce Biotech","summary":"Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication - Fierce Biotech","headline":"Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOaVp3bzdIMkwxbVlqQmU1bHF0cnlDV2ZKUmJ4Y1dHeVY3MjNENmNTQlhSd1ZGZC1kTTNDYnQyUVFaTS1DckdrdENLdUl5dEVzaDYwVUx1ZkFtX0RtanVsSFpDVzBEQUJUbmx2bWgtc2JtclBYQm5MdXJDcUt5OW4tR2ZFMkQ4TEZmaTV2eTdLVHMxN1pDdjFSVFJ5QWx1TVk2THlPaHlHWGVQSVJ6ajczQlVQbVVLWm9NWFhJMmpwMmJFZDZTQlZ1cjY2RjhiR1pwWC14dEE5dHZrQmxkSm14SS1mQmJoWHNBaHhWRmtHTDZNdjh0WjhhNHR3?oc=5","date":"2025-03-11","type":"pipeline","source":"European Medical Journal","summary":"Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights - European Medical Journal","headline":"Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5ORmFka1VEbEdnVW1SWVpmSGRuRU1TME9saEtyVFpnTjN5Zld4cktYbU9nd19vV0J5Y29hQXBfb3BvVDl3UzczcjN0bDVwZjdVVG9mS3BUX2NOeXY0OUFF?oc=5","date":"2025-02-14","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQd1hacVFpM2lNRmpKWXNrWnNpc18yUkNERmhsVTVNVmdyMXdOZVlKb3lMRzcyczZVcWpqSGgySk9DT3FIZnNJelFEVmcyUmFSUW9nU0E3a2F5XzBFcW82aEZTRlpydnhKRmRSa2xXbHd4V3hhTS1VM0NpT0lscHplNGNGMlRXTFNvMnR4WVVQc1JQNEF1QzFpT0xHMUotMUZJRUlkSHFWdlIwbzBBTDFvM0lIcEx5VGVueE56bWRfUWZnRGlkRlUyRFhuUGJ5LThxMDRBWWRTLW5jSFRhMldsaQ?oc=5","date":"2024-12-09","type":"pipeline","source":"BioSpace","summary":"Leukogene Therapeutics Welcomes Industry Veteran and Leader Dr. Sandeep Gupta as Its Chief Executive Officer - BioSpace","headline":"Leukogene Therapeutics Welcomes Industry Veteran and Leader Dr. Sandeep Gupta as Its Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5NOUt0bHgwbzFueHFTTWF0WC1Zb2o4Q2ZxVExLQXpPdE9ES25vWnZZQl9jb24tcFpRdEwyUzQ1VHN2ZnZWdFAzSEFqbGtrXzBSQVJ5OGxYLWZYaUlkVU15VWc3MGx2dkhsX2VGNlppejRpLVU?oc=5","date":"2024-05-17","type":"trial","source":"Oncology Pipeline","summary":"Erasca doubles down on RAS | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Erasca doubles down on RAS | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOb2ZsaWE3bWNDMEoyUC1CVFV4X1BrZ3NIcTc0LS03NjVVN0RuLURRLW1kZDhhVkVXT19uNlJXbFRuNWZGMS1kSkVxT2tyWHdKUVpMbGhRaUx2Ylh1NWR0WVNiMHcyTVhnck9qSzlsMVlHdFRULVdxV045YkRwTy1sbW1ITUd0MWF0d05BYjhaazlhT1VLTUNUVjJrdDVUQTF4bERaeWczNFFBN1B6eWw5dk1NdWhxM056Z25TczNacWUtQnljY2t1U1hEOW8yeGx0cWFsVlgwLWVHYVhseTMxWlNRZm92bGxKOWdTcl82WWcwaUgyUXZITFZB?oc=5","date":"2022-11-29","type":"trial","source":"PR Newswire","summary":"TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio - PR Newswire","headline":"TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}